Letter to the Editor
The opportunity cost of funding new medicines: an attempt to measure the invisible
El coste de oportunidad de financiar nuevos medicamentos: un intento de medir lo invisible
a University of Las Palmas de Gran Canaria, Department of Quantitative Methods in Economics and Management, Canary Islands, Spain
b Pennsylvania State University, Department of Health Policy and Administration, University Park, Pennsylvania, United States of America
c University of Alberta, School of Public Health, Edmonton, Alberta, Canada
d University of York, Centre for Health Economics, York, United Kingdom
Leído
2384
Vecesse ha leído el artículo
617
Total PDF
1767
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 9 | 214 | 48 | 262 |
| 2025 8 | 152 | 48 | 200 |
| 2025 7 | 155 | 42 | 197 |
| 2025 6 | 391 | 223 | 614 |
| 2025 5 | 220 | 45 | 265 |
| 2025 4 | 215 | 67 | 282 |
| 2025 3 | 420 | 144 | 564 |
